Stockscreener 앱 받기
11.25
1.72%
0.19
시간 외 거래:
11.26
0.010
+0.09%
Viatris Inc 주식(VTRS)의 최신 뉴스
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
What's in the Cards for Viatris Stock This Q4 Earnings? - Yahoo Finance
Hyperlipidemia Drugs Market Size to Promote USD 31.49 Bn by 2034 - GlobeNewswire Inc.
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline - Yahoo Finance
50 Years of Service: From Milkman’s Son to Advancing Access to Medicines - CSRwire.com
Viatris Inc.: Is It Time to Sell VTRS Stock Amid Declining Fundamentals?News and Statistics - IndexBox, Inc.
HAGENS BERMAN Alerts Viatris (VTRS) Investors to Pending Securities Fraud Class Action, Encourages Investors with Substantial Losses to Contact Firm’s Attorneys - ACCESS Newswire
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Hypovolemic Shock Market 2024-2031 | Pfizer Inc, Viatris Inc, - openPR
YieldBoost Viatris From 4.5% To 11.1% Using Options - Nasdaq
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Pediatric Healthcare Industry May See a Big Move |Boehringer Ingelheim, Glaxosmithkline, Viatris - openPR
3 Generic Drug Stocks to Watch - Morningstar
Viatris Stock Outlook: Is Wall Street Bullish or Bearish? - Nasdaq
Viatris Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - Nasdaq
Here's What to Expect From Viatris' Next Earnings Report - MSN
Viatris to Report Fourth Quarter and Full Year 2024 Financial Re - GuruFocus.com
Viatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 – Company Announcement - Financial Times
BofA Adjusts Price Target on Viatris to $11 From $12 -February 03, 2025 at 10:50 am EST - Marketscreener.com
Viatris Financial Results: Key Q4 and 2024 Performance Data Coming February 27 - StockTitan
Viatris And Idorsia Forge Global Partnership For Breakthrough Heart Attack Treatments - MSN
VTRS: 3 Hidden Bargains in the Healthcare Sector - StockNews.com
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
6 New 4-Star Stocks - Morningstar
Chris Davis Reduces Stake in Viatris Inc: A Strategic Portfolio Adjustment - GuruFocus.com
Viatris: Consolidate In 2025, Win In 2026How 'Phase 2' Of Business Plan May Play Out - Seeking Alpha
Here's What To Expect From Viatris' Next Earnings Report - Barchart
Lidocaine Patches Market Projected To Witness Substantial Growth, 2025-2032: Sanofi S.A., Viatris Inc., Galen - EIN News
Shell says head of downstream and renewables division Vigeveno to step down -January 23, 2025 at 02:27 am EST - Marketscreener.com
Taxanes Market: Projected Growth Trends through 2031 | Pfizer - openPR
Why Is Viatris Inc. (VTRS) Among the Best High-Yield Dividend Stocks to Invest In? - Insider Monkey
EU Antitrust Chief Ribera: Consumer Protections Remain Top Priority - PYMNTS.com
Is Viatris Inc. (VTRS) Among Wednesday’s Losers? - MSN
Viatris Launch Plans Continue To Drag On, But Confidence High On Quartet - News & Insights
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc (VTRS) Stock Price Down 4.56% on Jan 15 - GuruFocus.com
Is Viatris (VTRS) a Great Value Stock Right Now? - Yahoo Finance
Viatris To Present At J.P. Morgan Healthcare Conference; Webcast At 11:15 AM ET - Nasdaq
Viatris firm in Cork paid $4bn of dividends as sales fell ahead of announced plant closure - Business Post
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical Trials Progress and Therapeutic Advancements | Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, Roche - Barchart
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical - openPR
0.05%
1.53%
자본화:
|
볼륨(24시간):